IMW 2021 | Screening programs for plasma cell disorders
Irene Ghobrial, MD, of the Dana-Farber Cancer Institute, Boston, MA, and Maria-Victoria Mateos, MD, PhD, of the University of Salamanca, Salamanca, Spain, discuss the importance of screening and explain how a screening programme for early stages of myeloma could significantly improve survival outcomes for patients. Dr Ghobrial talks on screening high-risk individuals (over 10% risk of developing myeloma) and how the identification of even low-risk monoclonal gammopathy of undetermined significance (MGUS), as well as smoldering myeloma, can be monitored carefully to prevent progression. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Irene Ghobrial, MD, discloses links to Janssen, Sanofi, BMS, GSK, Karyopharm and Binding Site.
Maria-Victoria Mateos, MD, PhD, has received honoraria from lectures and participated in boards with Janssen, BMS-Celgene, AbbVie, Amgen, Takeda, GSK, Sanofi, Oncopeptides, Pfizer, Regeneron, Adaptive, Roche, Bluebird-bio and Sea-Gen.
